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ABSTRACT: Daptomycin is a lipopeptide antibiotic with strong
bactericidal effects against Gram-positive bacteria and minor
side effects on skeletal muscles. The type and magnitude of
the early effect of daptomycin on skeletal muscles of rats was
quantified by histopathology, examination of contractile proper-
ties, Evans Blue Dye uptake, and effect on the patch repair pro-
cess. A single dose of daptomycin of up to 200 mg/kg had no
effect on muscle fibers. A dose of 150 mg/kg of daptomycin,
twice per day for 3 days, produced a small number of myofibers
(0.22%) with loss of plasma membrane integrity and/or infiltra-
tion by neutrophils and/or macrophages. Multiple doses of dap-
tomycin are required for a quantifiable effect on skeletal
muscles of rats. Some fibers were Evans Blue Dye–positive but
were not yet infiltrated by neutrophils. This suggests that the
sarcolemma may be the primary target for the observed effects.
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Daptomycin is a Streptomyces roseosporus–derived lip-
opeptide antibiotic that has a strong and pro-
longed bactericidal effect against Gram-positive
bacteria,1 and it is especially effective against van-
comycin- and methicillin-resistant bacteria.2 Dapto-
mycin is usually well tolerated, but some patients
( 1.5%) develop side effects in skeletal muscles,1,3
although smooth and cardiac muscles are not
affected. The side effects on skeletal muscles are
not unique and have been reported previously for
other antibiotics.4
Currently, no conclusive data exist that clarify
the exact mechanisms responsible for any possible
effects or their magnitude that daptomycin might
have on skeletal muscles, and no factors have been
identified that might predispose some patients to
develop daptomycin-related side effects. Studies in
dogs have shown that multiple doses of daptomy-
cin may have a very mild effect on skeletal muscle
fibers.5 Although no direct data exist, the lipopep-
tide structure of daptomycin and its mechanisms
of action on bacteria6 suggest that the mechanisms
of action in mammalian cells might involve an
effect on the plasma membrane.
The objectives of this study were to character-
ize: early effects of intravenous administration of
daptomycin on the skeletal muscle of healthy
Sprague-Dawley rats; potential effects of daptomy-
cin on structural and functional properties of
selected skeletal muscles; and potential effects of
daptomycin on the plasma membrane repair
mechanisms involved in the patching of small sar-
colemmal breaches associated with normal muscle
activity. We hypothesized that the sarcolemma is
the primary target of daptomycin’s effect on skele-
tal muscle.
METHODS
Animals. Adult male Sprague-Dawley rats (4–6
months of age), obtained from Harlan Sprague-
Dawley (Indianapolis, Indiana), were used for the
experiments. For investigation of multiple doses
per day, rats were obtained from the vendor with
their carotid artery cannulas in place. Animal hous-
ing, operations, and subsequent animal care were
carried out in accordance with the guidelines of
the Unit for Laboratory Animal Medicine at the
University of Michigan.
Daptomycin Administration. Prior to dosing, dapto-
mycin was dissolved in saline (sterile 0.9% NaCl so-
lution) at a final concentration of 50 mg/ml. For
the single-dose experiments, non-cannulated rats
were used. Each of the rats (8–10 rats/group) in
both the daptomycin- and saline-treated groups
received a single dose through the tail vein and
were euthanized 72 hours later. Daptomycin was
administered at 100, 150, and 200 mg/kg. The sa-
line-treated group received a volume of saline that
was equal to the volume administered to the dap-
tomycin-injected rats. Gastrocnemius (GTN), tibi-
alis anterior (ATB), extensor digitorum longus
(EDL), plantaris, and biceps muscles were analyzed
in all rats by microscopic evaluation of the tissue
sections. A single dose was utilized initially to assess
the earliest changes in skeletal muscles associated
with daptomycin exposure.
In subsequent experiments, daptomycin was
administered twice daily to rats for 4 days to
increase the potential of an early effect on
skeletal muscle. A previous study demonstrated
that skeletal muscle changes associated with dapto-
mycin treatment in dogs are greatest for
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fractionated (multiple doses) daily dosing as com-
pared with once-daily dosing.5
For the multiple-dose investigations, rats in
both the daptomycin- and the saline-treated groups
had in-dwelling catheters in the carotid artery.
Eleven saline-treated and 11 daptomycin-treated
rats were used in the protocol for the twice-daily
dosing at 150 mg/kg per dose for 3 days (a total
of six doses). During each of the treatment days,
either daptomycin or saline was given through the
carotid artery catheters twice per day at approxi-
mately 8:00 A.M. and 4:00 P.M. On day 3, prior to
the second daptomycin dose, or for the control
rats prior to the saline administration, a 1-ml
blood sample was drawn from the carotid cannula
for analysis of serum creatine kinase (CK). CK val-
ues (IU/liter) were determined by the Animal
Diagnostic Laboratory at the University of Michi-
gan using an automated chemistry analyzer (Vet-
test 8008; IDEXX, Westbrook, Maine). The rats
were observed for any clinical signs of effects
throughout the study.
For the multiple-dose study, half of the rats
were injected with a 1% solution of Evans Blue
Dye (1% of body mass) following the last dose of
daptomycin (or saline) on day 3. In research stud-
ies on skeletal muscle, Evans Blue Dye is frequently
used as an early in vivo marker of myofiber dam-
age and, specifically, loss of cell membrane integ-
rity.7,8 On the morning of day 4, when the study
ended, rats were anesthetized with an intraperito-
neal dose of sodium pentobarbital. EDL and soleus
muscles were dissected from the right hind-limb of
each rat and contractile properties were evaluated.
GTN, ATB, EDL, soleus, plantaris, and biceps
muscles from left hind-limb and triceps muscle
from the left upper limb of each rat were pre-
served for histological analysis by embedding in
Triangel Biomedical Sciences (TBS) medium (Tri-
angle Biomedical Sciences, Durham, North Caro-
lina). After removal of the muscles, the animals
were euthanized with an overdose of the
anesthetic.
Measurements of Contractile Properties. On the
morning of day 4 of the experimental protocol,
both soleus (predominantly slow type 1 fibers) and
EDL (predominantly fast type 2a and 2b fibers)
muscles were dissected from each of the daptomy-
cin-treated and saline-treated rats. The muscles
were mounted in an experimental apparatus
designed for the measurement of contractile prop-
erties of intact muscles in vitro. The bath was filled
with an aerated Krebs–Henseleit buffer solution.
The solution was maintained at 25C, and pH was
maintained at approximately 7.4 by buffering with
a gas mixture of 95% O2 and 5% CO2. At comple-
tion of the measurements of contractile properties,
muscle length and mass were determined, and the
specific force was calculated.9 The force deficit was
measured as the maximum force generated 1 mi-
nute after two 30% stretches of the maximally acti-
vated muscle expressed as a percentage of the ini-
tial maximum force. The stretch protocol was
designed to detect substantial differences in sus-
ceptibility to contraction-induced injury.10 A proto-
col of two lengthening contractions was chosen to
prevent the confounding effects of fatigue that
may accompany multiple muscle contractions.
Histochemical and Immunohistochemical Analy-
sis. Muscles embedded in the TBS medium and
stored at 80C were subsequently sectioned on a
cryostat (12 lm) at the mid-belly region. Muscle
cross-sections were stained with hematoxylin and
eosin (H&E), as previously described.11 Muscle
cross-sections from the rats injected with Evans
Blue Dye were fixed in ice-cold acetone for 1 mi-
nute, dried, and coverslipped with Permount
(Fisher Scientific, Fair Lawn, New Jersey). The
number of affected fibers was quantified by micro-
scopic observations of the two or three adjacent
cross-sections for each of the muscles. Muscle
cross-sections were photographed at low magnifica-
tion, and cross-sectional areas were estimated by
outlining two or three adjacent cross-sections using
Image J software (NIH, Bethesda, Maryland;
http://rsb.info.nih.gov/ij/). Cross-sectional areas
of individual muscle fibers were estimated by out-
lining 100–200 fibers in three to five sections of
muscles from different rats. Mean fiber areas were
calculated separately for each of the muscles ana-
lyzed. To determine the approximate number of
total muscle fibers per section, the cross-sectional
area of a particular muscle section was divided by
the mean of the cross-sectional areas of muscle
fibers in a specific muscle.
For immunostaining to assess effects in type I
versus type II muscle fibers and for immmunostain-
ing of the patch repair proteins, sections were
incubated in a blocking buffer [20% calf serum in
phosphate-buffered saline with Tween 20 (PBST)]
for 1 hour and then in a solution of primary anti-
body overnight at 4C. The following primary anti-
bodies were used: mouse anti–slow myosin (type I
myosin; clone A4.84); mouse anti–fast IIa myosin
(clone A4.74), developed by Dr. Helen M. Blau
and obtained from the Developmental Studies
Hybridoma Bank developed under the auspices
of the NICHD and maintained by the University
of Iowa (Iowa City, Iowa); rabbit anti-laminin
(Chemicon International, Temecula, California);
mouse anti-dysferlin (Lab Vision Corp., Fremont,
California); rabbit anti-dysferlin (Affinity
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BioReagents, Rockford, Illinois); mouse anti–caveo-
lin-3 (BD Biosciences, San Jose, California); mouse
anti–LAMP-1 (Stressgen, Victoria, British Colum-
bia, Canada); rabbit anti–LAMP-2 (Abcam, Cam-
bridge, Massachusetts); mouse anti-macrophage
(Abcam); and rabbit anti-neutrophil elastase
(Abcam). Depending on the source of primary
antibody, 1-hour of room-temperature incubation
with Cy3-conjugated (red) anti-mouse or anti-rab-
bit secondary antibodies or Cy2-conjugated (green)
anti-rabbit secondary antibodies (all from Jackson
ImmunoResearch Laboratory, West Grove, Pennsyl-
vania) was done for visualization. Nuclei were
stained by 5-minute incubation with a 40-6-diami-
dino-2-phenylindole (DAPI) solution (Sigma Co.,
St. Louis, Missouri) in PBST. The sections were exam-
ined and photographed with a Leica microscope.
Adjustments in Data Analysis. The CK value for
one saline-treated rat and one daptomycin-treated
rat fell outside the range of 2 standard deviations
beyond the mean. These two data points were
excluded from the final figure in the Results sec-
tion. No difference was observed in the contractile
properties of either EDL or soleus muscles of rats
injected with Evans Blue Dye when compared with
those not injected. Based on these observations,
the data for the EDL and soleus muscles were com-
bined for rats injected with saline only and those
with saline/Evans Blue Dye. The data for the rats
given daptomycin only and daptomyocin/Evans
Blue Dye were also combined. One daptomycin-
treated rat had a much larger than usual number
of affected fibers in the triceps muscle, so the data
from this muscle were not used in this study. One
saline-injected rat also had an uncharacteristically
large number of affected fibers in two of the
muscles (GTN and ATB). These muscles were also
excluded from the study. The deletion of these
three muscles from our study was justified, because
they did not represent the general pattern found
in the other 81 muscles analyzed with twice-daily
dosing at 150 mg/kg per dose. We excluded two
daptomycin-treated rats and one saline-injected rat
from the analysis of Evans Blue Dye fluorescence,
because the low levels of fluorescence with Evans
Blue Dye in some, or all, of the muscles did not
allow the number of affected muscle fibers to be
assessed.
Statistical Analysis. Data are expressed as mean 6
standard error of the mean (SEM). A t-test analysis
was performed to compare the differences between
the saline- and daptomycin-treated groups of rats.
Differences were considered significant at P 
0.05.
RESULTS
Effect of a Single Dose of Daptomycin on Muscles of
Rats In Vivo. After a single intravenous dose of
daptomycin none of the supratherapeutic doses
given (100, 150, and 200 mg/kg) inflicted any
muscle damage, and no affected muscle fibers
were detected at 72 hours postinjection when ana-
lyzed in sections stained with H&E or Evans Blue
Dye (data not shown). The exception was one
GTN muscle in a rat treated with 150 mg/kg of
daptomycin and killed 72 hours postinjection. This
muscle had one small area infiltrated with macro-
phages and/or neutrophils (not shown). No differ-
ences were observed for the maximum or specific
isometric tetanic forces developed by the EDL and
soleus muscles of rats treated with a single injec-
tion of daptomycin (data not shown).
Effect of Twice-Daily Dosing of Daptomycin on
Muscles of Rats In Vivo. To study the early effects
of the continuous presence of daptomycin in tissue
fluids for several days we evaluated the effect after
multiple intravenous doses. In our initial studies
we investigated the effect of twice-daily suprathera-
puetic doses of 100 mg/kg or 150 mg/kg daptomy-
cin. Skeletal muscles were evaluated 48, 72, or
96 hours postinjection. With a twice-daily dose of
100 mg/kg for 2 days, no significant damage was
detected in any of the muscles analyzed. Only one
macrophage-infiltrated muscle fiber in one of the
cross-sections of a plantaris muscle was detected
(data not shown). At twice-daily doses of 150 mg/
kg for 4 days (a total of eight doses), multiple mus-
cle fibers infiltrated with macrophages were clearly
identified (Fig. 1) on H&E-stained muscle sections.
Some of the affected areas already showed signs of
ongoing satellite-cell activation and muscle fiber
regeneration (not shown).
For detailed analysis of the early effect of multi-
ple intravenous doses of daptomycin on rat skeletal
muscles in vivo and for the quantification of the
affected muscle fibers, a dose regimen of 150 mg/
kg twice daily for 3 days (total daily dose of 300
mg/kg) was selected. At this dose of daptomycin,
rats did not have any general toxicity and appeared
healthy, although they had a small number of eas-
ily detectable macrophage-infiltrated muscle fibers.
The damaged muscle fibers were grouped into two
or three selected areas per muscle, whereas the re-
mainder of the muscle was unaffected. Rats were
euthanized, and muscles were dissected on the
morning of day 4. For saline-treated and daptomy-
cin-treated rats, the total body masses were not dif-
ferent (Fig. 2), although small differences in mass
for several of the muscles were observed between
daptomycin- and saline-treated rats (Fig. 2).
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Daptomycin treatment was not associated with
any detectable functional effect on skeletal muscle
up to the highest dose tested. No differences were
observed for the maximum isometric tetanic force
(Po) developed by the EDL or soleus muscles (data
not shown). The specific maximum force (sPo, in
kN per m2) was used to evaluate any subtleties in
the individual differences in the response of indi-
vidual rats to this dosage of daptomycin (Fig. 3).
No significant difference was observed for sPo
between rats that received Evans Blue Dye and
those that did not. Therefore, the data points for
Evans Blue Dye–injected and non-injected rats in
Figure 3 were combined for both the saline- and
daptomycin-treated groups. For saline- and dapto-
mycin-treated rats, sPo was not different for the
EDL and soleus muscles (Fig. 3A, B). The force
deficit was measured in soleus muscle after two
30% stretches of the maximally activated muscle
(Fig. 3C). No differences were observed for force
FIGURE 1. H&E staining of muscle cross-sections of rats
injected twice per day for 4 days with 150 mg/kg daptomycin
and killed on day 5. Representative images of ATB (A, B), EDL
(C, D), and plantaris (E, F) muscles of rats at two different
magnifications are shown. All muscles in daptomycin-treated
rats had signs of structural muscle fiber damage, although the
number of damaged fibers varied in different muscles. Arrows
indicate damaged fibers infiltrated with macrophages. [Color fig-
ure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
FIGURE 2. Comparison of total body weight (grams) and mus-
cle mass (milligrams) for saline- and daptomycin-treated rats.
Asterisk represents statistically significant difference between
the saline- and daptomycin-injected groups (P < 0.05).
FIGURE 3. (A) Specific forces of EDL muscles of saline- and
daptomycin-treated rats. (B) Specific forces of soleus muscles
of saline- and daptomycin-treated rats. (C) The force deficit of
soleus muscle for saline- and daptomycin-treated rats. The
force deficit was measured as a percent of initial force 1 minute
after two 30% stretches to the muscle. (A–C) Data points repre-
sent individual muscles, and black lines represent the mean for
that group. No significant differences were observed between
rats that received saline and those that received daptomycin.
(D) Serum CK levels for saline- and daptomycin-treated rats.
Data points represent individual rats, and black lines represent
the group average. There was a statistically significant differ-
ence between the saline- and daptomycin-injected groups (P <
0.001).
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deficits between daptomycin- and saline-treated
groups. The daptomycin-treated group had a small,
but statistically significant increase in CK values
when compared with the saline-treated group (Fig.
3D).
Results of histological evaluations demonstrate
that only a small number of myofibers were
affected by daptomycin treatment (Figs. 4–7, and
Figs. S1 and S2 in the Supplementary Material).
Although muscles of the saline-treated rats had
essentially no fibers affected, the seven muscles an-
alyzed in each of the daptomycin-treated rats dis-
played various degrees of macrophage infiltration
and/or number of plasma membrane-breached
muscle fibers (Figs. 4–7). Affected muscle fibers
displayed characteristic grouping in one to three
FIGURE 4. H&E staining of skeletal muscles from saline-treated
rats [(A), (C), and (E) 3 days/twice per day] and daptomycin-
treated rats [(B), (D), and (F) 3 days/twice- daily treatment with
150 mg/kg]. Representative images of GTN (A, B), ATB (C, D),
and triceps (E, F) muscles of rats are shown. Bar ¼ 100 lm.
[Color figure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
FIGURE 5. Evans Blue Dye fluorescence of gastrocnemius
muscles from saline-treated [(A) and (C) 3 days/twice per day]
and daptomycin-treated [(B) and (D) 3 days/twice-daily treat-
ment with 150 mg/kg] rats. (C, D) Higher magnifications of (A)
and (B), respectively. Note grouping of the daptomycin-affected
fibers in a small area of the muscle (B, D) [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.].
FIGURE 6. Fluorescent microscopy of GTN muscle cross-sec-
tions of a rat injected with daptomycin and with Evans Blue Dye
for identification of affected fibers. Cross-sections were labeled
with antibody against laminin (green in all pictures) to visualize
muscle fibers and stained with DAPI [(B), (D), (F), and (H)] to
visualize nuclei. Antibody against slow myosin heavy chain [my-
osin type I; bright red staining in (A)–(D)] and antibody against
fast IIa myosin heavy chain [myosin type IIa; bright red staining
in (E)–(H)] were used for fiber typing. Arrows in (A)–(D) show
affected fibers labeled with antibody against myosin type I.
Arrowheads in (A)–(D) show Evans Blue Dye–positive (dark red
staining) affected fibers not labeled with antibody against myo-
sin type I, which are either type IIb or type IIa. Arrows in (E)–
(H) show affected fibers stained with antibody against myosin
type IIa. [Color figure can be viewed in the online issue, which
is available at www.interscience.wiley.com.]
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areas of the muscle, whereas the remainder of the
muscle was not affected (Figs. 4 and 5). Tables 1
and 2 show the results of quantification of number
of affected muscle fibers in seven different muscles
of saline- and daptomycin-treated rats.
The average cross-sectional area of muscle
fibers was 2800 lm2 in GTN muscle, 2450 lm2 in
ATB, 2318 lm2 in EDL, 3789 lm2 in soleus, 2684
lm2 in plantaris, and 2788 in lm2 triceps. The av-
erage number of muscle fibers per analyzed sec-
tion was 2860 for EDL, 2473 for soleus, 17,423 for
ATB, 5443 for plantaris, 16,561 for GTN, 10,835
for biceps, and 26,302 for triceps. Triceps muscle
cross-sections were the largest among all of the
muscles analyzed, and they showed the largest
absolute number of affected muscle fibers ( 40
fibers; Table 1). Nevertheless, the percentage of
affected muscle fibers was similar for soleus, GTN,
plantaris, and triceps muscles, with each averaging
0.11–0.22% (Table 2). The EDL, ATB, and
biceps muscles displayed a much lower percentage
of affected muscle fibers, 0.01–0.13% (Table 2).
Table 1. Number of affected muscle fibers in saline- and daptomycin-treated rats.
Group Type of analysis
Muscle
EDL Sol ATB PLT GTN Biceps Triceps
(n) (n) (n) (n) (n) (n) (n)
Saline-treated H&E Average 0.00 4.40 0.25 1.00 0.25 0.00 0.00
SEM 0.00 2.49 0.20 0.91 0.20 0.00 0.00
Daptomycin-treated H&E Average 0.29 5.43 11.14 7.71* 19.14* 0.71 40.00*
SEM 0.31 0.70 8.64 1.94 6.29 0.51 5.28
Saline-treated EBD Average 0.00 2.00 1.75 0.25 1.00 0.00 3.67
SEM 0.00 1.41 1.43 0.20 0.47 0.00 1.65
Daptomycin-treated EBD Average 3.50 4.80 10.86 8.17 32.00* 4.57 34.50*
SEM 2.94 1.06 4.51 4.90 13.09 4.58 13.95
H&E, hematoxylin and eosin stain; EBD, Evans Blue Dye fluorescence; EDL, extensor digitorum longus; Sol, soleus; ATB, tibialis anterior; PLT, plantaris;
GTN, gastrocnemius.
*Statistically significant difference (P < 0.05).
FIGURE 7. Representative images of the immunostaining of triceps muscle from saline-treated (A–C) and daptomycin-treated (D–I) rats
with rabbit anti-dysferlin [red in (A), (C), (D), and (F)] and mouse anti-dysferlin [red in (G) and (I)] antibodies. Nuclei were stained with DAPI
[blue in (B), (C), (E), (F), (H), and (I)]. Combined dysferlin/DAPI images are shown in (C), (F), and (I). Asterisks indicate neutrophils and
macrophages in the areas of damage. Arrows indicate areas of intact muscle fibers in a daptomycin-treated rat, with bright sarcolemmal
immunostaining for dysferlin. Arrowheads indicate faint sarcolemmal immunostaining for dysferlin in muscle fibers from saline-treated rats.
[Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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For four of the seven muscles, soleus, ATB, planta-
ris, and triceps, the two different methods for
counting the number of affected muscle fibers
(Evans Blue Dye fluorescence and H&E staining)
showed good correlation with regard to the num-
ber of affected fibers (Table 1). However, for the
other three muscles analyzed, EDL, GTN, and
biceps, Evans Blue Dye appeared to be more sensi-
tive for detecting an early effect. This observation
could reflect the fact that Evans Blue Dye detects
the early changes in plasma membrane integrity
(minutes–hours), whereas H&E only detects mus-
cle fibers that have been structurally altered. This
usually takes a longer time to occur (2–3 days).
The fiber type analysis of the affected fibers
using myosin heavy chain–specific antibodies and
fluorescently labeled secondary antibodies revealed
that both slow (type I) and fast (type II) muscle
fibers were affected (Fig. 6). The majority of
muscles analyzed (except for the soleus) were fast
muscles. Consequently, a larger portion of the
affected fibers in muscles analyzed were fast fibers
(Fig. 6).
In order to determine whether patch repair
proteins were involved in the response to the
plasma membrane breach in daptomycin-treated
rats, immunostaining with antibodies against dys-
ferlin (Fig. 7), caveolin-3 (Fig. S1), LAMP-1 (Fig.
S2), and LAMP-2 (not shown) was used. Each of
these proteins may be involved in the response to
rupture of the plasma membrane. The most in-
formative data were obtained with two different
antibodies against dysferlin (Fig. 7). Dysferlin im-
munostaining showed that, in daptomycin-treated
rats, the part of the sarcolemma of intact muscle
fibers that was in direct contact with the macro-
phage-infiltrated muscle areas showed the highest
intensity of dysferlin immunostaining (arrows in
Fig. 7D, F, G, I). Muscle fibers that did not have
direct contact with the affected areas displayed
weak sarcolemmal immunostaining for dysferlin.
Intact muscle fibers from saline-treated rats also
showed weak sarcolemmal immunostaining for dys-
ferlin (arrowheads in Fig. 7A, C). The two anti-dys-
ferlin antibodies showed similar results. The only
difference was that anti-dysferlin antibody pro-
duced in rabbits labeled nuclei in muscle sections
from both saline-treated (Fig. 7A, C) and daptomy-
cin-treated (Fig. 7D, F) rats, whereas antibody pro-
duced in mice did not label the nuclei (Fig. 7G,
I). Immunostaining with caveolin-3 antibodies was
less distinct, because the sarcolemma of all muscle
fibers showed very strong immunostaining with
this antibody. Consequently, small variations in im-
munostaining for caveolin-3 were more difficult to
detect (Fig. S1). Although severely damaged fibers
lost caveolin-3 immunostaining (asterisks in Fig.
S1), some of the intact fibers located close to the
affected areas appeared to display stronger caveo-
lin-3 immunostaining (arrows in Fig. S1A) than
the remaining muscle fibers of the section. The
brightest immunostaining with anti–LAMP-1 (Fig.
S2) and anti–LAMP-2 (not shown) antibodies was
localized to the affected areas. Anti–LAMP-1 and
anti–LAMP-2 antibodies showed similar results.
Neutrophils and macrophages in the area of dam-
age displayed the most prominent immunostaining
due to the large accumulation of lysosomes in
these cells (asterisks in Fig. S2). There was faint
punctate immunostaining in the sarcoplasm and in
the sarcolemma and/or endomysium of both
intact and damaged muscle fibers with both anti–
LAMP-1 (Fig. S2) and anti–LAMP-2 antibodies
(not shown).
DISCUSSION
This study was designed to investigate the early
functional and histological effect of daptomycin
on skeletal muscles of young healthy rats. The
effects were assessed by: (1) quantifying the type
and magnitude of effect on the different types of
muscle fibers; and (2) investigating plasma mem-
brane patch repair mechanisms. Our experiments
in adult rats after one dose of daptomycin show
that a single injection did not have any detectable
adverse effect on skeletal muscles even when high
Table 2. Percentage of affected muscle fibers in saline- and daptomycin-treated rats.
Group Type of analysis
No. of fibers
EDL Sol ATB PLT GTN Biceps Triceps
Saline-treated rats H&E Average 0.00 0.16 0.00 0.04 0.00 0.00 0.00
SEM 0.00 0.09 0.00 0.04 0.00 0.00 0.00
Daptomycin-treated rats H&E Average 0.02 0.22 0.06 0.15 0.11* 0.01 0.17*
SEM 0.02 0.03 0.05 0.05 0.03 0.00 0.04
Saline-treated rats EBD Average 0.00 0.07 0.01 0.00 0.00 0.00 0.01
SEM 0.00 0.05 0.01 0.00 0.00 0.00 0.01
Daptomycin-treated rats EBD Average 0.13 0.19 0.06 0.19 0.22* 0.04 0.18
SEM 0.10 0.04 0.02 0.13 0.09 0.04 0.11
*Statistically significant difference (P < 0.05).
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doses were administered. In our experiments, mul-
tiple doses of daptomycin were required to pro-
duce a measurable effect on skeletal muscles of
adult rats. Twice-daily administration at a supra-
therapeutic dose of 150 mg/kg over 3 days showed
morphologically detectable changes in 0.2% of
muscle fibers in several different muscles, but
there were no clinical signs associated with this
finding. The dose levels and dosing regimen were
specifically selected to evaluate early effects of dap-
tomycin on the sarcolemma and to avoid massive
damage to a large number of muscle fibers, which
would make it difficult to study the specific effects
on individual muscle fibers.
The mechanisms behind the adverse effects of
daptomycin on skeletal muscles have not been
delineated. The presence of the amino acid head
group and lipopeptide structure of daptomycin
make it most likely that daptomycin is inserted
into the outer leaflet of the plasma membrane
without translocation through the membrane. In
bacteria, daptomycin is inserted into the cytoplas-
mic membrane through calcium-dependent mech-
anisms that cause membrane depolarization and
death of the bacteria.6 Although no direct data
exist for skeletal muscles, the most likely mecha-
nism by which daptomycin has an effect involves
breaching of plasma membrane integrity through
gaps in the outer lipid-based leaflet of the sarco-
lemma, leakage of calcium from extracellular
compartments into the myofibers, and activation
of downstream mechanisms that lead to cell
death.
Our experiments show that multiple doses of
daptomycin at supratherapeutic levels have small,
but measurable effects on selected skeletal muscle
fibers of healthy adult Sprague-Dawley male rats,
ranging from 0.01% to 0.22% of the total number
of fibers analyzed. In three of the seven muscles
analyzed in this study, EDL, GTN, and biceps, it
appears that Evans Blue Dye fluorescence is more
sensitive than H&E staining. This may suggest that,
in these muscles, the initial effect of daptomycin is
on the sarcolemma. The affected muscle fibers
were usually grouped in two or three distinct areas
within a given muscle. It is not clear exactly what
predisposes specific groups of fibers so that they
display a measurable response to the daptomycin.
Naturally occurring damage to the sarcolemma, or
deficiency in the plasma membrane repair mecha-
nisms in the small number of myofibers, could
individually, or collectively, play a role. These
might be the groups of fibers in specific motor
units that are recruited most frequently on a daily
basis in rats and therefore undergo most of the
normal membrane ‘‘wear and tear’’ and high mem-
brane stress.
Skeletal muscle fibers have active plasma mem-
brane repair mechanisms that are involved in the
patching of small sarcolemmal breaches developing
during normal everyday muscle activity. Dysferlin,
caveolin-3, and LAMP have been reported previ-
ously to be important in the processes of regenera-
tion and repair of small-membrane damage and
tears in skeletal muscle fibers.12–15 The resealing of
damaged sarcolemma in muscle fibers is associated
with enrichment of dysferlin, caveolin-3, and LAMP
in the repaired membrane patches.12–15 It was
hypothesized that daptomycin administration could
interfere with repair of the breaches of the sarco-
lemma by inhibiting the fusion of vesicles contain-
ing dysferlin, LAMP, and caveolin-3 with the mem-
brane. Our immunostaining experiments show that
dysferlin was highly enriched in the sarcolemma of
the unaffected myofibers located in close proximity
to macrophage-infiltrated fibers. This observation
suggests that there were ongoing highly effective
plasma membrane repairs in the undamaged fibers.
Therefore, the plasma membrane repair mecha-
nisms that engage dysferlin-containing vesicles most
probably are not impaired in the skeletal muscle
fibers of daptomycin-treated rats. Although we can-
not exclude the possibility that, in the small num-
ber of daptomycin-affected, macrophage-infiltrated
myofibers detected in our experiments, some of the
naturally occurring defects in the plasma mem-
brane repair mechanisms predisposed them to the
daptomycin effect and subsequent neutrophil/mac-
rophage infiltration.
In conclusion, our findings show that the early
effect of daptomycin was localized to a small sub-
population of skeletal muscle fibers. It appears
that the early effects of daptomycin on skeletal
muscle may be due to loss of sarcolemmal integ-
rity. The factors that predispose myofibers to be re-
sponsive to an effect when they are treated with
daptomycin are uncertain, but could involve: (1)
the level of previous contractile activity of selected
motor units; and/or (2) the presence of small sar-
colemmal breaches that developed during normal
everyday muscle activity.
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